Our portfolio of medicines includes both blockbusters and niche products for all major therapeutic areas, with key product groups focused on the areas of:
- Cardiovascular system
- Anti-infectives for systemic use
- Central nervous system (CNS)
- Alimentary tract and metabolism
- Antineoplastic and immunomodulating agents
- Respiratory system
- Blood and blood forming organs
Leading the Way in Anti-infectives
The high level of Sandoz know-how in anti-infectives is based on decades of experience, particularly in producing intermediates. The wide range of products covers the various stages of the production process, from basic molecules to finished medicines.
The Global Leader in Biosimilars
Sandoz has long been a biotechnological competence center within Novartis, and has successfully taken the role as the pioneer and undisputed global leader in the emerging biosimilars market. Following the precedent-setting launch of human growth hormone Omnitrope® from 2006 in the EU and elsewhere, Sandoz also first launched its anemia medicine Binocrit® and neutropenia (oncology) treatment Zarzio® in the EU in 2007 and 2009 respectively.
A Full-Service Pharmaceutical Provider
Our activities cover every stage of the pharmaceutical value chain, from product development through to commercialization. Whatever we do, we combine highest quality standards with a strong customer focus. Providing high quality at an affordable price to all is the key to our success as a company.
Top ten retail products worldwide
|Amlodipine / Benazepril||Lotrelc®||Hypertension|
|Enoxaparin sodium injection||Lovenox®||Anti-coagulant|
|Lansoprazole||Prevacid®||Proton pump inhibitor|
|Omeprazole||Prilosec®||Ulcer & heartburn treatment|
|Simvastatin||Zocor®||Cholesterol lowering treatment|
Fluimucil®, Lotrel®, Augmentin®, Lovenox®, Duragesic®, Prevacid®, Cozaar®/Hyzaar®, Prilosec®, Zocor® and Prograf® are registered trademarks of: Zambon; Bristol-Myers Squibb; Novartis; GlaxoSmithKline; Sanofi-Aventis; Ortho-McNeil; Takeda Pharmaceuticals North America, Inc.; E.I. du Pont de Nemours and Company; AstraZeneca; Merck; and Astellas Pharma, respectively.